Core Insights - Pharvaris presented data on deucrictibant, an oral bradykinin B2 receptor antagonist, demonstrating its effectiveness in treating hereditary angioedema (HAE) attacks, with 78.6% of participants experiencing substantial symptom resolution within 24 hours [1][2] Group 1: Clinical Efficacy - Deucrictibant achieved substantial symptom resolution in 78.6% of participants within 24 hours after a single dose, compared to 22.4% for placebo [2] - The Treatment Outcome Score (TOS) questionnaire indicated that the majority of HAE attacks treated with deucrictibant resulted in significant symptom improvement [2] - The effectiveness of deucrictibant was found to be comparable to high-efficacy injectable therapies, with higher satisfaction scores than other oral prophylactic treatments [4] Group 2: Safety and Satisfaction - The treatment satisfaction questionnaire showed that participants reported higher satisfaction with deucrictibant's effectiveness compared to placebo, driven by favorable scores across all measured subdomains [4] - The side effects and convenience scores were consistent between deucrictibant and placebo, indicating a favorable safety profile [4] Group 3: Future Developments - Pharvaris plans to publish data from ongoing open-label extensions to further establish the long-term safety and efficacy of deucrictibant [2] - The company is exploring additional indications and pipeline expansion opportunities to address unmet needs in the HAE community [2][5] Group 4: Product Information - Deucrictibant is being developed in two formulations: an immediate-release capsule for acute treatment and an extended-release tablet for prophylactic use [6] - The company aims to provide effective, safe, and easy-to-administer alternatives for all sub-types of HAE [7]

In addition to these findings, Pharvaris continues to evaluate the ever-changing treatment landscape in HAE to best address the unmet need of people living with HAE through presentation of real-world evidence of treatment behaviors. Evaluation of Treatment Satisfaction Questionnaire for Medication (TSQM) in participants in the Phase 2 CHAPTER-1 clinical study showed satisfaction with the effectiveness of deucrictibant is higher to placebo and is in-line with separate observations of high-efficacy injectable ...

ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunolog ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Recent Business Updates and Highlights Development Pipeline Exhibit 99.1 Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Zug, Switzerland, April 10, 2024 – Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. "20 ...

Exhibit 99.1 Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Zug, Switzerland, April 5, 2023 – Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update. "Our first in-patient data readout of deucrictibant in people living with HAE ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR ...

Pipeline • Top-line Phase 1 data demonstrate extended-release PHVS719 suitable for once-daily dosing. The Phase 1 pharmacokinetics (PK) study of PHVS719 included 8 healthy volunteers dosed in an open-label • Phase 1 pharmacokinetics study demonstrates PHVS719 well tolerated with extended-release profile supporting once-daily dosing • Orphan Drug Designation for PHA121 granted by FDA • RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks ongoing; top-line data anticipated in 4Q22 • C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

© 2022 © 2022 Pioneering science for patient choice March 2022 Disclaimer This Presentation may contain certain "forward‐looking statements" within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements other than statements of historical factors contained in this Presentation, including statements regarding our future financial condition, results of operations and/or business achievements, including, without limitation, statements containing the words "b ...